Clinical Impact of 5 ʹMYC or 3ʹMYC Gain/loss Detected by FISH in Patients with Aggressive B-cell Lymphomas

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma [1]. The standard therapy for patients with DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and 60-70% of patients are cured using this regimen [1, 2]. For patients who are resistant to frontline chemotherapy or relapse (especially within the first 2 years), alternative chemotherapy regimens, stem cell transplantation (SCT) or other treatment options such as chimeric antigen receptor (CAR) T-cell therapy may improve patient outcome.

Source: Cancer Genetics and Cytogenetics - December 18, 2022 Category: Genetics & Stem Cells Authors: Guilin Tang, Shaoying Li, Gokce A. Toruner, Preetesh Jain, Zhenya Tang, Shimin Hu, Jie Xu, Joanne Cheng, Melissa Robinson, Francisco Vega, L. Jeffrey Medeiros Source Type: research